Early treat-to-target in RA: outcomes held up at ten years

Design

10-year follow-up of a randomised treat-to-target trial cohort

Population

179 of 230 patients with early rheumatoid arthritis from ARCTIC

Primary outcome

Remission, radiographic progression, function and survival at 10 years

Effect

82% DAS remission; median Sharp score change 2.0 (IQR 0.5 to 4.5); survival similar to population

The ARCTIC trial applied strict treat-to-target therapy for two years in 230 patients with early rheumatoid arthritis. This 10-year follow-up, published in Annals of the Rheumatic Diseases on 22 September 2026, assessed 179 of the 218 surviving patients.

Ten years after diagnosis, 82% were in DAS remission. Radiographic progression was small, with a median change in modified Sharp score of 2.0 (IQR 0.5 to 4.5) over the decade. Physical function and quality of life approached population norms, and survival was similar to the general population. Patients who reached sustained remission at two years had lower disease activity and better function at ten years than those who did not.

The follow-up is observational, and the 18% who did not attend may have fared differently. But the findings support the central idea of current recommendations: aim for remission early and adjust treatment until it is reached. For patients in India starting on conventional synthetic DMARDs, the strategy of frequent review and escalation matters more than any particular drug.

• Aim for remission in early rheumatoid arthritis and review frequently until it is reached
• Escalate treatment promptly when targets are missed at scheduled reviews
• Measure disease activity with a composite score at each visit
• Explain to patients that early sustained remission was linked to better function a decade later

Why it matters

It shows the payoff of early tight control lasts a decade, not just the length of a trial.

Don't overread it

Observational long-term follow-up; the link between early remission and later outcomes is an association.

The statistics, in plain English

A median Sharp score change of 2.0 over ten years is very little joint damage on X-ray. Comparing patients who did or did not reach early remission is not randomised, so other differences between them may contribute.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.